Moderna mRNA cancer vaccine cuts melanoma recurrence in phase 3 trial
Updated results from the KEYNOTE-942 trial show Moderna's personalised mRNA vaccine combined with Keytruda reduced the risk of melanoma recurrence or death by 49 percent versus Keytruda alone — results robust enough to support expansion to additional cancer types.
- Personalised mRNA vaccines are manufactured per-patient using tumour mutation sequences from individual biopsies
- Phase 3 results confirmed the phase 2b signal across a larger cohort with longer follow-up duration
- Moderna is now running trials in lung, kidney, and head-and-neck cancers using the same platform